ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO152

Low Plasma Insulin-Like Growth Factor-1 Associates with Increased Mortality in CKD Patients with Reduced Muscle Strength

Session Information

Category: Nutrition, Inflammation, and Metabolism

  • 1401 Nutrition, Inflammation, Metabolism


  • Zhimin, Chen, Karolinska Institutet, Stockholm, Sweden
  • Lindholm, Bengt, Karolinska Institutet, Stockholm, Sweden
  • Heimburger, Olof, Karolinska Institutet, Stockholm, Sweden
  • Barany, Peter F., Karolinska Institutet, Stockholm, Sweden
  • Stenvinkel, Peter, Karolinska Institutet, Stockholm, Sweden
  • Chen, Jianghua, Zhejiang University, Hangzhou, China
  • Qureshi, Abdul Rashid Tony, Karolinska Institutet, Stockholm, Sweden

Chronic kidney disease (CKD) leads to metabolic and nutritional abnormalities including resistance to insulin-like growth factor-1 (IGF-1) action. Low plasma IGF-1 concentration as well as low handgrip strength (HGS), a reliable and easy-to-perform nutritional parameter, are independent predictors of increased mortality in CKD patients (pts). We hypothesized that low muscle strength enhances the negative impact of low IGF-1 on survival in CKD.


We included 685 CKD pts (62% males; median age 58 years) including 75 CKD 3-4 pts, 361 incident dialysis pts, 70 prevalent peritoneal dialysis pts and 179 prevalent hemodialysis pts. Baseline measurements of IGF-1, HGS, nutritional status (by subjective global assessment, SGA), lean body mass index (LBMI), and metabolic and inflammatory biomarkers potentially linked to IGF-1 were analysed in relation to mortality during follow up period of up to 5 years during which 208 pts (30.4%) died. We compared survival in four groups with high or low (cut-offs defined by ROC curve analysis) levels of IGF-1 and HGS.


Pts with low IGF-1 were older, had lower body mass index (BMI), HGS and LBMI, more likely to have diabetes, CVD and malnutrition (SGA >1), and had sensitivity C-reactive protein (hsCRP) levels. During 5 years of follow-up, 208 pts (30.4%) died. Pts with Low IGF-1 + Low HGS had markedly increased mortality rate: In competing-risks regression analysis, sub-hazard ratio (SHR) of pts with Low HGS + Low IGF-1 was 2.3 times higher than for pts with High HGS + Low IGF-1. Low IGF-1 + Low HGS was independently associated with all-cause mortality after adjustments for age, sex, diabetes, CVD, SGA, smoking, hsCRP, albumin and LBMI.


Low IGF-1 together with low HGS - but not low IGF-1 together with high HGS - was independently associated with increased all-cause mortality suggesting that the effect of IGF-1 on mortality in CKD patients depends on nutritional status.


  • Commercial Support